AOD-9604 research at Raw Wholesale Peptides

AOD 9604 human trials

The human result settles the central question for me. AOD-9604 did not demonstrate statistically significant weight loss against placebo in its pivotal obesity trial, and development stopped around 2007. Across the programme, roughly six trials involved about 900 adults with obesity; the human safety and tolerability report describes exposure lasting from 7 days to 24 weeks and oral study amounts reaching 54 milligrams daily. Those figures record the trials, with no established treatment regimen emerging from them.

Reported adverse effects resembled placebo, the comparison treatment containing no active drug. That is useful information about tolerability during the observation periods. The obesity programme still missed the result it had been built to obtain. I take the failed weight endpoint seriously even alongside the reassuring safety summary.

AOD9604 and AOD 9604 are other spellings of AOD-9604. Its expanded name, Anti-Obesity Drug 9604, preserves an ambition that the trials failed to fulfil.

Fatty-acid synthesis

AOD-9604 is a synthetic, altered fragment of growth hormone, made of 16 amino acids. A bridge between two cysteines closes a loop in the chain. The design sought fat-metabolism effects while avoiding growth hormone’s growth-promoting, IGF-1-raising and blood-sugar effects; AOD-9604 does not bind the growth hormone receptor. The metabolic work on the fragment concerns cells and rodent models.

The older experiment is especially useful for the language around it. In fat- and liver-cell preparations, a growth-hormone part-sequence inhibited acetyl-CoA carboxylase, an enzyme involved in making new fatty acids. That is an antilipogenic action: less new fat being made. Calling every such result “fat burning” smooths away a distinction I think deserves to survive.

The 1983 experiment tested the hormone and a part-sequence. It supplies mechanistic history, while the later AOD-9604 work and the human programme answer their own questions.

Obese mice and a missing receptor

In the obese-mouse study comparing the fragment with growth hormone, both increased fat oxidation and produced weight loss. Another mouse experiment included animals without functional beta-3 adrenergic receptors, proteins involved in the response to signals that trigger fat breakdown.

With those receptors missing, the lasting weight and fat response disappeared, even though short-lived increases in energy expenditure and fat oxidation persisted. In ordinary obese mice, repeated treatment increased the RNA instructions for making those receptors in fat tissue. I enjoy this experiment because it separates a brief fuel-use response from the sustained weight response. The mice provide that distinction; human weight-loss efficacy remained unproved.

AOD 9604 lab tested: which test?

“Lab tested” leaves the question open until the test is named. AOD 9604 peptide research has included cell assays, animal toxicology, measurements of breakdown in blood and human trials. A claim about a particular batch’s identity or purity would require results for that batch. The clinical trial results cannot establish the contents or sterility of an unrelated supply.

The non-clinical safety and metabolism paper reported no genotoxic or toxicological concerns in the tested rats and primates. Its approximately 3-minute intravenous half-life came from a pig model. The peptide broke down through sequential removal of amino acids from one end; oral absorption was also demonstrated in the animal work. Human pharmacokinetics after subcutaneous administration remain unpublished in the evidence discussed here.

The distinction matters because a rapid clearance measurement in one animal, by one route, offers a very small answer to a much larger safety question.

Cartilage scores in rabbits

There is also a knee osteoarthritis experiment involving 32 rabbits. After inducing arthritis, the investigators gave AOD9604 into the joint, with or without hyaluronic acid. Visible and microscopic cartilage-degeneration scores were lower than in the saline group. Cartilage is the smooth tissue covering the ends of bones at a joint.

This result concerns rabbit cartilage scores. Human joint benefit and pain relief remain unestablished. A human osteoarthritis trial would be a substantial next step in my estimation; the rabbit finding leaves that step ahead.

Community reports

Community accounts often describe little noticeable fat loss and few day-to-day complaints. These are anecdotes, not clinical evidence. Some posters describe less water retention, puffiness or hand tingling than they associate with growth hormone; others mention energy, mood or appetite changes. Diet and exercise frequently changed at the same time, leaving the cause of any visible change unresolved. Human trials offer no support for claims of fat loss confined to an injection site.

The longest human trial exposure discussed here was 24 weeks. Rare harms and longer-term effects remain uncertain even when short-term tolerability looks reassuring. Research material also raises separate questions about identity, purity and sterility.

Regulatory status

AOD-9604 has no FDA-approved treatment use and no medical approval from a major drug authority. FDA’s Pharmacy Compounding Advisory Committee reviewed it in December 2024; that historical review alone does not settle current compounding eligibility. The applicable rules require a current check by a pharmacist.

WADA prohibits AOD-9604 during and outside competition as a growth-hormone fragment. Dedicated analytical tests can detect it even when the usual growth hormone isoform assay does not. An athlete’s anti-doping question therefore remains separate from whether a trial reported weight loss.

The tesamorelin trials measured a particular compartment of abdominal fat in adults with HIV. The MOTS-c experiments include mouse performance and human biomarker observations. Neither supplies the successful AOD-9604 human weight result that is missing here.